Compare Abeona Therapeutics Inc (ABEO) vs Vanguard Information Technology Index Fund ETF (VGT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Vanguard Information Technology Index Fund ETF — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Vanguard Information Technology Index Fund ETF trades at $115.11. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Vanguard Information Technology Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | VGT | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | — |
52-Week High | $7.23 | $125.77 |
52-Week Low | $4.17 | $83.59 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
The Vanguard Information Technology ETF (VGT) trades at $116.37, up 1.51% on the day, with technical indicators showing a mixed but slightly bullish bias. The fund recently executed an 8-for-1 stock split and maintains a low 0.09% expense ratio, positioning it as a cost-efficient vehicle for broad tech exposure. Financial media sentiment is generally positive, highlighting VGT's strong long-term track record and diversification benefits compared to more concentrated tech ETFs.
The outlook for VGT is tied to the broader technology sector's performance, particularly hyperscaler capital expenditure and semiconductor cycles. Key opportunities include exposure to AI-driven growth through a diversified portfolio. Primary risks involve sector concentration, market volatility, and potential valuation pressures if tech earnings growth decelerates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Vanguard Information Technology Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →
